prurigo nodularis Archives -

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline

Roche adds to pipeline with Poseida, Kiniksa deals

https://pharmaphorum.com/news/roche-adds-to-pipeline-with-poseida-kiniksa-deals/

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology

FDA grants speedy review to Dupixent rare skin disease

https://pharmaphorum.com/news/fda-grants-speedy-review-to-dupixent-rare-skin-disease/

Sanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising

Dupixent scores a first in rare skin disease prurigo nodularis

https://pharmaphorum.com/news/dupixent-scores-a-first-in-rare-skin-disease-prurigo-nodularis/

prurigo nodularis